In this article, we outline updates on the clinical development of savolitinib, a novel, reversible c-MET kinase inhibitor conditionally approved in China for treatment of advanced non-small cell lung cancer (NSCLC) patients harboring MET exon 14 skipping mutation (METex14). Here, MET is linked to non-small cell lung carcinoma.